Format

Send to

Choose Destination
Orthop Clin North Am. 2014 Jul;45(3):403-16. doi: 10.1016/j.ocl.2014.03.006.

Use of bisphosphonates in orthopedic surgery: pearls and pitfalls.

Author information

1
Department of Orthopedic Surgery, Massachusetts General Hospital, Boston, MA, USA; Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Orthopedic Surgery, Boston Children's Hospital, Boston, MA, USA. Electronic address: slozanocalderon@mgh.harvard.edu.
2
Department of Orthopedic Surgery, Massachusetts General Hospital, Boston, MA, USA; Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Orthopedic Surgery, Boston Children's Hospital, Boston, MA, USA.
3
Department of Orthopedic Surgery, Massachusetts General Hospital, Boston, MA, USA.
4
Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Boston, MA, USA; Department of Orthopedic Surgery, Boston Children's Hospital, Boston, MA, USA.

Abstract

Bisphosphonates are medications known to decrease bone resorption by inhibiting osteoclastic activity. They are the first-line therapy for the treatment of osteoporosis because a significant body of literature has proved their efficacy in reducing the risk of fracture in the hip, spine and other nonvertebral osseous sites. In addition, the use of bisphosphonates has significantly decreased morbidity and increased survival, and they have also proved to be cost-effective. Unexpected adverse effects have been reported recently, but the benefit of bisphosphonates use outweighs the risks. This article reviews the current use of bisphosphonates in orthopedic surgery.

KEYWORDS:

Bisphosphonates; Bone turnover; Jaw osteonecrosis; Osseous metastasis; Osteoclast; Osteoporosis; Paget disease; Pathologic fractures

PMID:
24975766
DOI:
10.1016/j.ocl.2014.03.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center